Triazolam — Membership Pricing

Other medications in Mental Health

• Trifluoperazine
• Valproate
• Varenicline
• Venlafaxine
• Vilazodone
• Vortioxetine
• Zaleplon
• Ziprasidone

About Triazolam

Triazolam, commonly known by its brand name Halcion, is a prescription medication used for the short-term treatment of insomnia, particularly for those who have trouble falling asleep. At TheDrugClub, we understand the importance of accessible medication. Our mission is to help members find significant savings on prescriptions like triazolam, making your path to a restful night more affordable.

What Triazolam Treats

Triazolam is primarily prescribed for the short-term management of insomnia. It's particularly effective for individuals who experience difficulty initiating sleep. Because of its rapid action and short duration, it helps you fall asleep quickly without causing excessive morning grogginess. However, due to its potential for dependence and withdrawal symptoms, it's typically recommended for use over a short period, usually no more than 7 to 10 consecutive nights, or as directed by your healthcare provider.

How Triazolam Works

As a benzodiazepine, triazolam works by enhancing the effects of a natural chemical in the brain called gamma-aminobutyric acid (GABA). GABA is a neurotransmitter that reduces brain activity. By increasing GABA's effects, triazolam produces a calming effect, slowing down the central nervous system. This action helps to induce sleep, reduce anxiety, and relax muscles. It's important to use triazolam exactly as prescribed by your doctor to ensure safety and effectiveness.

Typical Costs of Triazolam

The cost of triazolam can vary significantly based on several factors, including whether you're getting the generic version (triazolam) or the brand-name Halcion, the dosage (e.g., 0.125 mg, 0.25 mg), the quantity prescribed, and the pharmacy you choose. Without insurance or a prescription savings program, a typical supply (e.g., 30 tablets) could range from approximately $30 to over $100 for the generic, and considerably more for the brand name. Prices can fluctuate widely between different pharmacies, even within the same [city

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Triazolam is approved for (FDA label)

Triazolam is indicated for the short-term treatment of insomnia (generally 7 to 10 days) in adults. Triazolam is a benzodiazepine indicated for the short-term treatment of insomnia (generally 7 to 10 days) in adults.

Source: Read the full FDA label on DailyMed. Label effective date: July 10, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Triazolam (FDA label)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS • Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [see Warnings and Precautions (5.1) , Drug Interactions (7.1) ] . • The use of benzodiazepines, including triazolam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing triazolam and throughout treatment, assess each patient's risk for abuse, misuse, and addiction [see Warnings and Precautions (5.2) ]. • The continued use of benzodiazepines, including triazolam, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of triazolam after continued use may precipitate acute withdrawal reactions, which can be life-threatening.

Source: FDA prescribing information (DailyMed). Set ID: 5add318e-11b9-42f8-b052-0d8cebb32fcf. SPL document ID: 27655a51-bab0-4bde-bd82-c15aa61f4705. Label effective date: July 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Triazolam (FDA label)

• Tablets: 0.125 mg white, imprinted with "G3717" • Tablets: 0.25 mg powder blue, scored, imprinted with "G3718" • Tablets: 0.125 mg ( 3 ) • Scored tablets: 0.25 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 5add318e-11b9-42f8-b052-0d8cebb32fcf. SPL document ID: 27655a51-bab0-4bde-bd82-c15aa61f4705. Label effective date: July 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Triazolam (FDA label)

The following serious adverse reactions are discussed in greater detail in other sections: • Risks from Concomitant Use with Opioids [see Warnings and Precautions (5.1) ] • Abuse, Misuse, and Addiction [see Warnings and Precautions (5.2) ] • Dependence and Withdrawal Reactions [see Warnings and Precautions (5.3) ] • Persistent or Worsening Insomnia [see Warnings and Precautions (5.4) ] • "Sleep-driving" and Other Complex Behaviors [see Warnings and Precautions (5.5) ] • Central Nervous System Manifestations [see Warnings and Precautions (5.6) ] • Effects on Driving and Operating Heavy Machinery [see Warnings and Precautions (5.7) ] • Patients with Depression [see Warnings and Precautions (5.9) ] • Neonatal Sedation and Withdrawal Syndrome [see Warnings and Precautions (5.10) ] • Compromised Respiratory Function [see Warnings and Precautions (5.11) ] Most common adverse reactions (incidence ≥4% and twice placebo) are drowsiness, dizziness, light-headedness, and coordination disorder/ataxia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Viatris at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 5add318e-11b9-42f8-b052-0d8cebb32fcf. SPL document ID: 27655a51-bab0-4bde-bd82-c15aa61f4705. Label effective date: July 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Triazolam (FDA label)

Triazolam is contraindicated in: • Patients with known hypersensitivity to triazolam, any of component of triazolam, or other benzodiazepines. Reactions consistent with angioedema (involving the tongue, glottis, or larynx), dyspnea, and throat closing have been reported and may be fatal. • Concomitant administration of strong cytochrome P450 (CYP 3A) enzyme inhibitors (e.g., ketoconazole, itraconazole, nefazodone, lopinavir, ritonavir) [see Warnings and Precautions (5.8) , Drug Interactions (7.1) ]. • Known hypersensitivity to triazolam or other benzodiazepines ( 4 ) • Concomitant use with medications that significantly impair the oxidative metabolism mediated by cytochrome P450 3A (CYP 3A) including ketoconazole, itraconazole, nefazodone, and several human immunodeficiency virus (HIV) protease inhibitors ( 4 , 5.8 , 17 )

Source: FDA prescribing information (DailyMed). Set ID: 5add318e-11b9-42f8-b052-0d8cebb32fcf. SPL document ID: 27655a51-bab0-4bde-bd82-c15aa61f4705. Label effective date: July 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Triazolam (FDA label)

• Persistent or Worsening Insomnia : Since sleep disturbances may be the presenting manifestation of a physical and/or psychiatric disorder, symptomatic treatment of insomnia should be initiated only after a careful evaluation of the patient. The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated. ( 5.4 ) • "Sleep-driving" and Other Complex Behaviors : Complex behaviors such as "sleep-driving" have been reported. The use of alcohol and other central nervous system (CNS) depressants with sedative-hypnotics appears to increase the risk, as well as doses exceeding the maximum recommended dose. ( 5.5 ) • CNS Manifestations : An increase in daytime anxiety, abnormal thinking, and behavioral changes have been reported.

Source: FDA prescribing information (DailyMed). Set ID: 5add318e-11b9-42f8-b052-0d8cebb32fcf. SPL document ID: 27655a51-bab0-4bde-bd82-c15aa61f4705. Label effective date: July 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Triazolam (FDA label)

• Use with Opioids : Increase the risk of respiratory depression ( 7.1 ) • Use with Other CNS Depressants : Produces additive CNS depressant effects ( 7.1 ) • Use with CYP 3A4 Inhibitors : Increased risk of adverse reactions ( 4 , 5.8 , 7.1 ) 7.1 Drugs Having Clinically Important Interactions With Triazolam Table 2 includes clinically significant drug interactions with triazolam [see Clinical Pharmacology (12.3) ] . Table 2: Clinically Important Drug Interactions with Triazolam Opioids Clinical implication The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABA A sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists.

Source: FDA prescribing information (DailyMed). Set ID: 5add318e-11b9-42f8-b052-0d8cebb32fcf. SPL document ID: 27655a51-bab0-4bde-bd82-c15aa61f4705. Label effective date: July 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.